Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program

Vandana Singh
2 min read
1
In this article:

  • As previously announced, Valneva SE (NASDAQ: VALN) said it would not invest in further COVID-19 vaccine development, VLA2001, without a new partnership. However, it is completing the remaining clinical studies and submissions.

  • Last week, the Committee for Medicinal Products for Human Use of the European Medicines Agency backed VLA2001 approval in adults as a booster dose after at least seven months following primary vaccination with VLA2001 (homologous booster dose) or with an adenoviral vector COVID-19 vaccine (heterologous booster dose).

  • Related: Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study.

  • In Phase 3 Study COV-Compare study, neutralizing antibodies six months after the second dose of the primary vaccination with VLA2001 was non-inferior compared to the active comparator AZD1222, better known as AstraZeneca Plc's (NASDAQ: AZN) Covishield.

  • The fold decline of neutralizing antibodies over six months after a second vaccination with VLA2001 was similar to the active comparator and less pronounced than other licensed COVID-19 vaccines.

  • Additionally, VLA2001-304 Phase 3 study in older adults showed that VLA2001 was well tolerated when administered as a two-dose or three-dose immunization.

  • In this age group, a two-dose vaccination with VLA2001 was inferior regarding geometric mean titers and seroconversion rates compared to younger adults.

  • After two doses, immunogenicity in older adults was at a level that could correlate with 60-70% vaccine efficacy against original SARS-CoV-2. A third dose further increased immunogenicity with a vaccine efficacy of over 90%.

  • Price Action: VALN shares traded flat at $12.29 on the last check Thursday.

  • Photo Via Wikimedia Commons

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories